focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,108.00
Bid: 12,108.00
Ask: 12,112.00
Change: -64.00 (-0.53%)
Spread: 4.00 (0.033%)
Open: 12,180.00
High: 12,188.00
Low: 12,096.00
Prev. Close: 12,172.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET OPEN: European markets mixed ahead of ECB decision

Thu, 11th Apr 2024 08:54

(Alliance News) - European equities lacked direction early Thursday morning, ahead of an interest rate decision from the European Central Bank this afternoon.

The FTSE 100 index opened up 2.10 points at 7,963.31. The FTSE 250 was down 4.02 points at 19,797.73, and the AIM All-Share was up 1.13 points, 0.2%, at 756.32.

The Cboe UK 100 was up 0.1% at 796.00, the Cboe UK 250 was up 0.1% at 17,216.17, and the Cboe Small Companies wasdown 0.2% at 14,720.34.

In European equities on Thursday, the CAC 40 in Paris was up 0.2%, while the DAX 40 in Frankfurt was down slightly.

Thursday's economic calendar has an interest rate decision from the European Central Bank. It is due out at 1315 BST and markets are widely expecting the central bank to keep rates unchanged.

Investors will be eyeing the press conference which will follow, in hopes of some hints on the ECB's expected timing of rate cuts.

Across the Atlantic, hopes of a June rate cut were almost crushed on Wednesday, sending stocks in New York lower.

In the US on Wednesday, Wall Street ended lower, with the Dow Jones Industrial Average down 1.1%, the S&P 500 down 1.0% and the Nasdaq Composite down 0.8%.

Inflation data from the US on Wednesday came in stronger than expected, forcing the market to reassess the timing of an easing in monetary policy.

According to the Bureau of Labor Statistics, the year-on-year rate of US consumer price inflation picked up to 3.5% last month, from 3.2% in February, taking it further above the Fed's 2% inflation target.

The rate of consumer price inflation had been expected to pick up to just 3.4%, according to FXStreet cited consensus.

There were also minutes from the US Federal Reserve to digest on Wednesday.

Federal Reserve officials said they required more confidence that inflation was moving towards its 2% target before cuts to interest rates could be considered, minutes from the March Federal Open Market Committee meeting showed.

"Wednesday's inflation report dealt a significant blow to the Federal Reserve's aspirations for a soft landing as, once again, inflation outpaced expectations," said SPI Asset Management's Stephen Innes.

"Hotter-than-expected prices force Fed officials back into a cautious stance, where they must await further clarity on inflation dynamics and tangible signs of economic deceleration before even entertaining a rate cut before Q4."

Still to come on Thursday, there is a producer price reading from the US. It is expected to deliver more data which will dampen hopes of interest rate cuts.

According to FXStreet, the US producer price index is expected to come in at 2.2% in March, picking up from 1.6% in February.

The pound was quoted at USD1.2539 early on Thursday in London, down compared to USD1.2546 at the equities close on Wednesday. The euro stood at USD1.0737, lower against USD1.0743. Against the yen, the dollar was trading at JPY153.10, up compared to JPY152.88.

In the FTSE 100, AstraZeneca rose 1.0%.

The pharmaceutical company said it plans to increase its dividend for 2024 by 7% to USD3.10 per share, from USD2.90 a year prior.

Chair Michel Demare said: "This uplift is in line with our progressive dividend policy, which remains unchanged, and reflects the continuing strength of AstraZeneca's investment proposition for shareholders."

Kingfisher jumped 3.8%, after HSBC raised the retailers broker rating to 'buy'.

The bank also raised Smiths Group's rating to 'buy'. The engineering company's stock rose by 2.1%.

In the FTSE 250, Darktrace rose by 8.3%, thanks to a jump in its annual guidance.

The Cambridge, England-based cybersecurity company said at constant currency rates, annualised recurring revenue at March 31 was USD731.1 million, representing growth of 24% from USD583.6 million a year ago. Revenue in its third quarter jumped 24% to USD176.1 million from USD139.2 million a year prior.

Looking ahead, Darktrace narrowed its guidance range for constant currency ARR, and now expects growth of between 22.3% and 23.0%, from 21.5% to 23.0% previously.

The firm also raised its expectations for year-on-revenue growth and adjusted Ebitda margin, and now expects revenue growth of at least 25.5%, up from its previous 23.5% and 25.0% range.

On London's AIM, Lok'n Store shares rose by 16%.

Brussels-based Shurgard, the largest developer, owner and operator of self-storage facilities in Europe, said it has reached an agreement to buy the self storage provider for GBP378 million.

Under the agreement, Lok'n Store shareholders will receive 1,110 pence in cash per share. This represents a 6% premium to the closing price of 958p on Wednesday.

Chair Andrew Jacobs said: "Lok'nStore's board believes the offer represents significant value for Lok'nStore's shareholders, recognising the quality of Lok'nStore's real estate portfolio and operational strength. Over the years Lok'nStore has built a unique portfolio of purpose-built self-storage assets. We believe that integrating Lok'nStore's assets and operations into Shurgard is highly complementary considering Lok'nStore's asset locations and positioning in its markets.

In Asia on Thursday, the Nikkei 225 index in Tokyo was down 0.4%. In China, the Shanghai Composite was up 0.2%, while the Hang Seng index in Hong Kong was down 0.2%. The S&P/ASX 200 in Sydney closed down 0.4%

Brent oil was quoted at USD90.47 a barrel early in London on Thursday, up from USD89.31 late Wednesday. Gold was quoted at USD2,338.60 an ounce, higher against USD2,334.91.

Still to come on Thursday's economic calendar, there is a producer price reading from the US, as well as the weekly initial jobless claims.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
12 May 2024 13:25

Pfizer and AstraZeneca announce new investments of nearly $1 billion in France

PARIS, May 12 (Reuters) - Leading healthcare companies Pfizer and AstraZeneca announced on Sunday new investments in France worth a total of nearly $1 billion, ahead of the start of this year's annual 'Choose France' business summit.

Read more
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.